The stock of Tourmaline Bio Inc (TRML) has seen a -2.61% decrease in the past week, with a -9.70% drop in the past month, and a 20.12% flourish in the past quarter. The volatility ratio for the week is 7.71%, and the volatility levels for the past 30 days are at 8.06% for TRML. The simple moving average for the last 20 days is -6.53% for TRML stock, with a simple moving average of -20.97% for the last 200 days.
Is It Worth Investing in Tourmaline Bio Inc (NASDAQ: TRML) Right Now?
The 36-month beta value for TRML is at 2.04. Analysts have varying views on the stock, with 8 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for TRML is 16.37M, and currently, shorts hold a 19.50% of that float. The average trading volume for TRML on May 20, 2025 was 326.67K shares.
TRML) stock’s latest price update
Tourmaline Bio Inc (NASDAQ: TRML)’s stock price has decreased by -8.99 compared to its previous closing price of 16.63. However, the company has seen a -2.61% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-19 that NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) — Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, will host a conference call and webcast on Tuesday, May 20, 2025 beginning at 8:30 a.m. ET to present topline results from the Phase 2 TRANQUILITY trial evaluating pacibekitug in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease. Members of Tourmaline management will be joined by Dr. Deepak L. Bhatt, Director of the Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai in New York. Dr. Bhatt also serves as the Chair of Tourmaline’s Cardiovascular Scientific Advisory Board (for which he is compensated).
Analysts’ Opinion of TRML
Many brokerage firms have already submitted their reports for TRML stocks, with Chardan Capital Markets repeating the rating for TRML by listing it as a “Buy.” The predicted price for TRML in the upcoming period, according to Chardan Capital Markets is $70 based on the research report published on April 23, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see TRML reach a price target of $42. The rating they have provided for TRML stocks is “Outperform” according to the report published on March 06th, 2025.
BMO Capital Markets gave a rating of “Outperform” to TRML, setting the target price at $50 in the report published on December 06th of the previous year.
TRML Trading at -3.96% from the 50-Day Moving Average
After a stumble in the market that brought TRML to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.19% of loss for the given period.
Volatility was left at 8.06%, however, over the last 30 days, the volatility rate increased by 7.71%, as shares sank -13.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.18% upper at present.
During the last 5 trading sessions, TRML fell by -3.67%, which changed the moving average for the period of 200-days by -8.38% in comparison to the 20-day moving average, which settled at $16.18. In addition, Tourmaline Bio Inc saw -25.37% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TRML starting from Kulkarni Sandeep Chidambar, who purchase 1,779 shares at the price of $14.85 back on Aug 21 ’24. After this action, Kulkarni Sandeep Chidambar now owns 7,000 shares of Tourmaline Bio Inc, valued at $26,418 using the latest closing price.
Kulkarni Sandeep Chidambar, the CEO of Tourmaline Bio Inc, purchase 5,221 shares at $13.79 during a trade that took place back on Aug 16 ’24, which means that Kulkarni Sandeep Chidambar is holding 5,221 shares at $71,998 based on the most recent closing price.
Stock Fundamentals for TRML
Current profitability levels for the company are sitting at:
- -2461.15 for the present operating margin
- 0.25 for the gross margin
The net margin for Tourmaline Bio Inc stands at -2071.72. The total capital return value is set at -0.35. Equity return is now at value -26.14, with -25.63 for asset returns.
Based on Tourmaline Bio Inc (TRML), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -428.67.
Currently, EBITDA for the company is -89.73 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 8767.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 33.87.
Conclusion
In conclusion, Tourmaline Bio Inc (TRML) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
